The patients in the study will be randomized to receive either a vaccine that is combined with an immune system stimulant or the immune system stimulant alone. The immune system stimulant is called OPT-821 and is an immunological booster. If the trivalent vaccine can stimulate the patient’s immune system to develop antibodies which recognize and target the GM2, GD2 and GM3 sugars that are over expressed on the surface of most sarcomas, then the patient’s antibodies could attack and kill any remaining sarcoma cells potentially preventing the recurrence of sarcoma.

For more information about the trial and to take a short questionnaire to see if you qualify click here.

YOU MAY HAVE THE OPTION TO PARTICIPATED IN A CLINICAL TRIAL

This clinical trial is testing a novel vaccine desinged to instruct the immune system to destroy any sarcoma cells that remain in the body after surgery.

This vaccine is given as an outpatient treatment with the goal of preventing or delaying sarcoma recurrence.

Participants may receive, and no cost, study-related:

• Medical care
• Study vaccine
• Laboratory work and evaluations

Participants must be within 8 weeks of their surgery and meet other eligibility requirements, agree to undergo the study required procedures and after a thorough discussion of the study, give written consent to participate in the study.

See if you qualify here

For Individuals Experiencing End of Dose Wearing Off

This trial is to evaluate the safety and efficacy of the investigational product tozadenant as adjunctive therapy in levodopa-treated patients with end of dose wearing off.

Tozadenant has a novel mechanism of action which, if proven safe and efficacious and approved by the FDA, could represent the first new treatment modality for Parkinson’s disease in more than 20 years. Participants must: Be between the ages of 30 & 80 Have a good response to levodopa and be taking at least 4 doses of a levodopa containing medication per day Be taking levodopa continuously for at least the previous 12 months and experiencing some daily (24-hour clock) OFF time

Study-related office visits, laboratory work and medication are at
no cost.

To learn more about this trial and see if you qualify to participate, Click Here

Over the course of Parkinson’s Disease (PD), a substantial number of patients develop a wearing-off effect which refers to the fact that the benefits you receive from your dopaminergic medications wear off before you are due to receive your next dose. This means you may go for a period of time with relatively uncontrolled motor symptoms.

If your Parkinson’s medication is wearing off, consider participating in a clinical trial.  Visit www.clinicaltrialspotlight.com to learn about ongoing clinical trials for Parkinson’s.

Why is it important to continue research for new treatment options for Advanced Prostate Cancer?
The American Cancer Society estimates that 32,050 men will die of advanced prostate cancer in 2010.  Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer, and accounts for about 11% of cancer-related deaths in men. Men of African or African-American descent are twice as likely to be diagnosed with prostate cancer as men of European descent, and are often diagnosed with advanced prostate cancer. These statistics indicate that we must continue to look for alternative treatment options for patients with advanced prostate cancer.
Clinical trials in advanced prostate cancer are an important means of discovering new treatment options. In 2004, the results of two Phase 3 studies (TAX327 and SWOG S9916) established docetaxel as a new standard for first-line therapy in patients with hormone refractory prostate cancer (HRPC). Docetaxel remained the only approved treatment option in HRPC until June of this year when cabazitaxel was approved for patients that had failed docetaxel. Once again this approval was based on Phase 3 clinical trial data (TROPIC). Both docetaxel and cabazitaxel were approved based on ~ 3 month increased overall survival in their respective patient populations. Although the approval of any drug that increases survival is welcome, clearly there is an ongoing need for clinical trials investigating new drug options using innovative mechanisms of action to fight the battle against advanced prostate cancer.

What is the investigational drug Ipilimumab and how does it work?
Ipilimumab is a member of a class of agents referred to as immunotherapeutics or immunotherapy agents. These agents are designed to use a patient’s own immune system to fight disease. One theory as to how cancer cells continue to grow is that they somehow hide themselves from immune cells or that the patient’s immune response is not robust enough to kill all the cancer cells. The goal of immunotherapy agents is to either boost the immune response or somehow make cancer cells more visible to the immune system so that they can be better targeted and killed.

Ipilimumab is a fully human monoclonal antibody, which means that it binds to a specific target (antigen) within the body.  Specifically, ipilimumab binds to a molecule found on T-cells that is called Cytotoxic T Lymphocyte Antigen 4 (CTLA-4). CTLA-4’s normal role is to act as part of a breaking mechanism that keeps our immune system from over responding. When a foreign antigen is presented to a T-cell, a response is generated so that the body’s immune system attacks and destroys the foreign cells. In order to keep the immune system from generating too much of a response, which could lead to immune cells attacking non-foreign or “self” cells, CTLA-4 works in conjunction with other molecules to put a “brake” on the immune response. By binding to CTLA-4, ipilimumab removes this “brake”, potentially leading to a more robust immune response. The clinical trial described below, sponsored by Bristol-Myers Squibb (BMS CA184043), is designed to determine if bone-directed radiotherapy combined with ipilimumab treatment leads to an increase in survival benefit for patients with metastatic prostate cancer that have received prior docetaxel.

How do I get more information on this Research Study?
About 800 patients throughout the world, approximately 300 in the United States, are expected to participate in this study. Participants may be in the study for 1 year or more, depending on how they respond to the study therapy. The study is currently enrolling in the US and globally, with enrollment expected to continue until July 2011.
Participants in this study may receive, at no cost, study-related: medical care, study medication, laboratory work and evaluations.
Medical insurance is not necessary to participate in this study, and study-related travel/parking may be reimbursed.

To participate, you must:
have a diagnosis of prostate cancer that has metastasized to the bone
have previously undergone at least 1 chemotherapy regimen containing docetaxel (Taxotere)
A study physician will discuss complete study criteria with you

For more information about this study including the location of study centers across the country, visit www.clinicaltrialspotlight.com or clinicaltrials.gov and search under NCT00861614, then speak with your physician to discuss if participating in this study might be of benefit to you.

It develops gradually, often starting with a barely noticeable tremor in just one hand. But while tremor may be the most well-known sign of Parkinson’s disease, the disorder also commonly causes a slowing or freezing of movement.

Friends and family may notice that your face shows little or no expression and your arms don’t swing when you walk. Speech often becomes soft and mumbling. Parkinson’s symptoms tend to worsen as the disease progresses.

While there is no cure for Parkinson’s disease, many different types of medicines can treat its symptoms. If you are searching for new Parkinson’s treatment options for this condition consider participating in a Parkinson’s clinical research study.

Did you know that people searching for clinical trials on the web prefer to have colorful visual and/or audio information about a trial rather than just plain text? We have learned that providing clinical trial information in visual and audio formats further prompts the viewer to complete the pre-screening questionnaire, as compared to information provided in written text.

The team behind this website has over 25 years of direct patient recruitment experience. They know exactly where to place the banner ads for maximum effect and which strategic partners will be in direct contact with your specific patient population.

You no longer have to go through the expense of creating a study-specific website—Clinical Trial Spotlight becomes that website. Registering as a Sponsor and uploading all of your lay trial information is a very easy and immediate process. Once the upload is complete, and banner ads are ready, we start heightening the awareness of your trial directly to your specific patient population.

As more and more clinical trials are being conducted worldwide, the pool of potential participants narrows further and further. You can no longer rely on the “standard” methods of recruiting patients for your trial. You need to have a strategy to reach beyond the surface level of eligible patients.

Clinical Trial Spotlight is your answer. This website is heavily promoted to the general public through such media as: banner ads on lay user’s websites, articles and ads in print magazines, banner ads and informational email blasts through non-profit organizations, mailers through medical data warehouses just to name a few. We have access to your specific patient population.

To learn about how you can benefit from listing your trial on Clinical Trial Spotlight, fill out the form at the right to become a registered Sponsor.

By Registering with Clinical Trial Spotlight and creating your own free profile, you will have the option to “opt-in” and be notified of new clinical trials that match your specific area of medical interest as they become available.

Clinical Trial Spotlight’s Mission

Because your health is what matters, we are committed to providing you with an easy-to-use format to review the most up-to-date, complete information about a given clinical trial.